GENB · CIK 0002100782
What Generate Biomedicines, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for GENB. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- proposed 100% tariffs on imported branded pharmaceuticalsmedium
Exposed to the September 2025 proposal for 100% tariffs on imported branded/patented pharmaceuticals (unless building US manufacturing), which could raise the cost of APIs and bulk drug products for its trials.
“For example, in September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity.”
SEC filing →As of 2026
Sole-source dependency
- sole/limited-source suppliers for APIs & drug substancesmedium
Fabless (no manufacturing facilities); depends on sole-source and limited-source suppliers for raw materials, APIs, drug products and drug substances used in its product candidates.
“We depend on sole source and limited source suppliers for certain raw materials, APIs, drug products, drug substances and other materials used in our product candidates.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch